An Ethiopian umbrella review estimated perinatal depressive symptoms at 22.49% across 8 systematic reviews and meta-analyses. Antenatal and postnatal rates were similar, so the burden spans the whole perinatal window rather than clustering only after delivery.1 Research Highlights Overall pooled prevalence was 22.49%: Necho et al. combined 8 Ethiopian systematic reviews and meta-analyses covering 28 …
Postpartum depression (PPD) is a serious mental health issue affecting many new mothers, impacting their well-being and their ability to bond with their child. Recent research suggests that inflammation could play a crucial role in the development of depression, opening the door to innovative treatments. A new case report highlights the potential of celecoxib, an …
Allopregnanolone agonists represent a promising new class of medications for treating depressive disorders. Evidence suggests that allopregnanolone agonists exhibit rapid-onset of antidepressant action – particularly in women with postpartum depression (PPD). Key facts: Allopregnanolone is a neurosteroid that acts as a positive allosteric modulator of GABAA receptors and is decreased in depressive disorders. The allopregnanolone …